Breast Cancer – Page 3 – Medical News Asia

PARPi talazoparib FDA approved for deleterious gBRCAm HER2‑negative breast cancer

18 October 2018/0 Comments/in Breast Cancer, US FDA Onc\Haem Approvals, Oncology, Targeted Therapies/by scienterrific

On October 16, 2018, the FDA approved PARP-inhibitor talazoparib (Talzenna®, Pfizer) for use in patients with deleterious or suspected deleterious germline BRCA-mutated locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Patients should be selected for the PARP inhibitor (PARPi)-treatment using an FDA-approved companion diagnostic (CDx) for talazoparib.

Early breast cancer treatment in China remains conservative

23 September 2018/0 Comments/in Breast Cancer, China, Oncology, Chemotherapy, Surgery/by scienterrific

Breast-conserving surgery is uncommon in China, and despite routinely performing SLNB the uptake of the ACOSOG Z0011 study recommendation to treat selected sentinel node-positive patients with whole breast irradiation and adjuvant systemic therapy instead of ALND remains low at only 17% of Chinese centres. These were the key findings of a national survey among 520 Chinese hospitals.

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

22 August 2018/0 Comments/in Breast Cancer, Medical News Asia, Genitourinary Cancer, Lung Cancer, Melanoma & Skin Cancer, Oncology, Immunotherapy, Translational Research/by scienterrific

Biosceptre has announced the initiation of its Phase 1 clinical study with the peptide vaccine BIL06v. BIL06v is a peptide-protein conjugate that recruits the patient’s immune system to make antibodies specifically targeted at nfP2X7-expressing cancer cells resulting in tumour cell death.

Talazoparib in advanced breast cancer patients with a germline BRCA1/2 mutation

19 August 2018/1 Comment/in Breast Cancer, Oncology, Chemotherapy, Targeted Therapies/by scienterrific

Single-agent PARP-inhibition with talazoparib is associated with an improved progression-free survival (PFS) and better patient-reported outcomes (PRO) when compared to chemotherapy alone in patients with advanced breast cancer (ABC) and a germline BRCA1/2 mutation, as reported by the investigators of the Phase III EMBRACA study (NCT01945775) in the New England Journal of Medicine.

Ribociclib FDA label updated to include pre- and perimenopausal women

19 July 2018/0 Comments/in Breast Cancer, US FDA Onc\Haem Approvals, Oncology, Endocrine Therapy, Targeted Therapies/by scienterrific

On July 18, 2018, the US FDA expanded the ribociclib (Kysqali©, Novartis) approval. Ribociclib plus an aromatase inhibitor as initial endocrine-based therapy is no longer limited to postmenopausal HR-positive, HER2-negative advanced or metastatic breast cancer patients alone and now includes pre- and perimenopausal women. Furthermore, the FDA has added the combination ribociclib plus fulvestrant as initial endocrine-based therapy for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.

ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised

19 June 2018/2 Comments/in Breast Cancer, ASCO 2018 Annual Meeting, Conferences, Oncology, Chemotherapy, Immunotherapy, Targeted Therapies, Translational Research/by Stijn van den Borne, MSc

Breast cancer: a front-runner when it comes to the development of novel therapeutic strategies. With the advent of newer targeted- and immunotherapies, oncologists have an increment of options to offer their patients. The American Society of Clinical Oncology’s (ASCO) 2018 Breast Cancer track offered an extensive look at the latest advancements and updates from on-going trials covering the various subtypes of breast cancer.

Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?

25 October 2017/1 Comment/in Breast Cancer, Oncology, Endocrine Therapy/by Stijn van den Borne, MSc

Can chemotherapy be avoided in women with hormone-sensitive breast cancer? This is a prominent question in the treatment of breast cancer around the globe.

Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?

5 July 2017/0 Comments/in Breast Cancer, Oncology, Endocrine Therapy/by Stijn van den Borne, MSc

One in six women with early, operable breast cancer may not need years of adjuvant hormonal therapy after primary treatment. This was the conclusion of a recent study published in JAMA (the Journal of the American Medical Association) Oncology.

ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data

9 November 2016/2 Comments/in Breast Cancer, Conferences, Oncology, Endocrine Therapy/by Stijn van den Borne, MSc

Cyclin-dependent Kinase 4 and 6 (CDK4/6) inhibitors have shown clinical activity in patients with endocrine-resistant metastatic breast cancer. During the European Society for Medical Oncology (ESMO) Annual Meeting 2016, significant updates on studies with CDK4/6 inhibitors ribociclib, palbociclib and abemaciclib were presented.

ASCO Guideline NeoAdjuvant Chemotherapy for Ovarian Cancer Updated

27 September 2016/0 Comments/in Breast Cancer, Gynaecological Cancer, Oncology/by Stijn van den Borne, MSc

In women with stage IIIC or IV ovarian cancer, primary cytoreductive surgery (PCS) may be preferred when there is a high chance to achieve cytoreduction to <1 cm with acceptable morbidity. This was concluded by an expert panel who published clinical guidelines in the Journal of Clinical Oncology (JCO) this week.